Skip to main content
    I

    Insmed Inc (INSM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $122.88
    +1.72 (+1.42%)

    Market Cap: $26.58B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Insmed Inc (INSM) Financials: Revenue, Profit and Cash Flow

    Updated Oct 29, 2026. Financial statements from company filings, amounts in US dollars.

    Insmed reported revenue of $606.42M for the fiscal year ended Dec 31, 2025, up 66.7% from the year before. That year, net income was -$1.28B with a net margin of -210.5%, operating cash flow was -$935.01M and free cash flow was -$967.58M. The quarter ended Sep 30, 2026 had revenue of $524.43M and net income of -$100.32M.

    Revenue and Margins

    Over the 7 years to Dec 2025, revenue grew from $9.84M, a compound annual rate of 80.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$606.42M+66.7%79.7%-205.6%-210.5%
    Dec 2024$363.71M+19.2%76.4%-241.5%-251.2%
    Dec 2023$305.21M+24.4%78.5%-232.5%-245.6%
    Dec 2022$245.36M+30.2%77.5%-186.4%-196.3%
    Dec 2021$188.46M+14.6%76.6%-199.0%-230.6%
    Dec 2020$164.41M+20.5%75.7%-161.3%-178.9%
    Dec 2019$136.47M+1287.6%82.3%-172.4%-186.4%
    Dec 2018$9.84MN/A75.4%-3124.9%-3297.2%
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$606.42M$363.71M$305.21M$245.36M$188.46M$164.41M$136.47M$9.84M$0$0
    Cost of revenue$122.94M$85.74M$65.57M$55.13M$44.15M$39.87M$24.21M$2.42M$0$0
    Gross profit$483.49M$277.96M$239.63M$190.23M$144.31M$124.54M$112.25M$7.41M$0$0
    Research and development$771.09M$598.37M$571.01M$397.52M$272.74M$181.16M$131.71M$145.28M$109.75M$122.72M
    Operating income-$1.25B-$878.25M-$709.63M-$457.32M-$375.09M-$265.23M-$235.25M-$307.34M-$188.92M-$173.40M
    Net income-$1.28B-$913.77M-$749.57M-$481.53M-$434.65M-$294.09M-$254.34M-$324.28M-$192.65M-$176.27M
    EBITDA-$1.22B-$857.85M-$686.84M-$446.98M-$361.27M-$248.20M-$205.85M-$300.56M-$185.60M-$170.56M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$524.43M$425.49M$305.96M$263.84M$142.34M$107.42M$92.82M$104.44M$93.42M$90.34M$75.50M$83.69M
    Gross profit$446.21M$358.27M$258.54M$219.62M$112.98M$79.34M$71.55M$78.29M$72.25M$69.38M$58.04M$65.25M
    Operating income-$89.37M-$1.55M-$153.32M-$319.75M-$366.00M-$312.88M-$248.14M-$230.41M-$213.43M-$288.90M-$145.50M-$178.27M
    Net income-$100.32M-$13.24M-$163.56M-$328.49M-$370.02M-$321.69M-$256.58M-$235.55M-$220.52M-$300.61M-$157.09M-$186.06M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $540.96M exceeded cash and equivalents by $30.52M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$2.26B$2.03B$1.33B$1.66B$1.24B$796.15M$742.30M$604.56M$462.05M$237.96M
    Current assets$1.79B$1.62B$929.06M$1.27B$837.04M$622.89M$555.19M$518.95M$389.44M$168.41M
    Cash and equivalents$510.44M$555.03M$482.37M$1.07B$716.78M$532.76M$487.43M$495.07M$381.17M$162.59M
    Total liabilities$1.53B$1.74B$1.66B$1.57B$833.04M$520.27M$480.63M$396.29M$100.99M$83.47M
    Short-term debt$0$16.50M$10.64M$8.13M$10.14M$12.56M$12.26MN/A$55.57M$54.79M
    Long-term debt$540.96M$1.10B$1.16B$1.13B$566.59M$356.32M$335.94M$316.56M$55.57M$54.79M
    Shareholder equity$738.98M$285.38M-$331.92M$87.95M$410.47M$275.88M$261.67M$208.27M$361.06M$154.48M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$2.23B$2.10B$2.08B$2.26B$2.36B$2.48B$1.80B$2.03B$2.05B$1.81B$1.16B$1.33B
    Total liabilities$1.50B$1.35B$1.37B$1.53B$1.42B$1.23B$1.70B$1.74B$1.57B$1.77B$1.62B$1.66B
    Cash and equivalents$396.56M$544.76M$582.19M$510.44M$334.76M$1.28B$403.25M$555.03M$461.45M$1.25B$595.73M$482.37M
    Shareholder equity$726.21M$757.49M$704.85M$738.98M$945.57M$1.25B$99.16M$285.38M$483.42M$38.82M-$464.81M-$331.92M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$935.01M-$683.88M-$536.25M-$400.44M-$363.30M-$219.35M-$250.65M-$257.98M-$159.62M-$146.71M
    Capital expenditures$32.56M$21.92M$13.29M$9.88M$7.29M$6.24M$42.27M$13.09M$3.00M$4.20M
    Free cash flow-$967.58M-$705.80M-$549.53M-$410.32M-$370.59M-$225.59M-$292.92M-$271.07M-$162.62M-$150.91M
    Investing cash flow-$64.58M-$583.17M-$223.60M-$34.58M-$64.28M-$6.82M-$42.27M-$14.81M-$3.00M-$4.20M
    Financing cash flow$954.07M$1.34B$168.44M$793.27M$612.55M$271.00M$285.28M$386.74M$381.09M$30.67M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$36.46M-$88.83M-$222.74M-$247.60M-$219.76M-$205.57M-$262.09M-$195.98M-$180.92M-$122.95M-$184.03M-$130.82M
    Capital expenditures$5.63M$6.26M$3.48M$16.59M$2.42M$3.48M$10.07M$6.77M$3.69M$6.78M$4.68M$2.15M
    Free cash flow-$42.09M-$95.09M-$226.22M-$264.19M-$222.18M-$209.05M-$272.16M-$202.75M-$184.60M-$129.74M-$188.71M-$132.97M
    Last 12 quarters

    Frequently Asked Questions About INSM

    What is Insmed's annual revenue?

    Insmed reported revenue of $606.42M for the fiscal year ended Dec 31, 2025.

    How fast is Insmed's revenue growing?

    Revenue was up 66.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 35.2%.

    Is Insmed profitable?

    No. Insmed reported net income of -$1.28B for the fiscal year ended Dec 31, 2025, with a net margin of -210.5%.

    How much free cash flow does INSM generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$935.01M minus capital expenditures of $32.56M produced free cash flow of -$967.58M.

    How much debt does Insmed have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $540.96M, short-term debt of $0 and cash and equivalents of $510.44M.